• Eli Lilly and Company is trading 2% down at $1089.60 today.
  • The U.S. Food and Drug Administration (FDA) issued warning letters to telehealth companies on June 17, 2026, for marketing false and misleading claims about compounded versions of weight-loss drugs, including Lilly's tirzepatide.
  • This news suggests stock-specific pressure and profit-taking amidst concerns related to the GLP-1 market.